Aeolus to Present at Stifel Nicolaus' Annual Healthcare Conference
MISSION VIEJO, CA--(Marketwire -09/06/11)- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS.OB - News) (Pinksheets:AOLS.OB - News), a biotechnology company that is leveraging up to $140M of government funding in developing a platform of a new class of broad-spectrum catalytic antioxidant compounds as medical countermeasures to radiation exposure to develop them in oncology indications, today announced that it will be presenting at the Stifel Nicolaus Annual Healthcare Conference in Boston. Russell Skibsted, the Company's Chief Financial Officer, will be presenting a corporate update, including an overview of its recent contract with the Biomedical Advanced Research and Development Authority (BARDA), with options valued at $118 million.
The presentation is scheduled for Wednesday, September 7, at 3:50 p.m. ET. The presentation will be webcast and is available through the investor relations section of the Company's website atwww.aeoluspharma.com.
About Aeolus Pharmaceuticals
Aeolus Pharmaceuticals is developing a new class of catalytic antioxidant compounds that protects healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with funding by the US Government, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118 million, to efficiently develop the compound for use in oncology.
The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' amended Annual Report on Form 10-K/A for the year ended September 30, 2010. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.